https://www.selleckchem.com/pr....oducts/finerenone.ht
ns of pulmonary/respiratory symptoms, which requires further investigations. Q-SLAQ and the original SLAQ performed equally well, demonstrating that the shorter Q-SLAQ can safely be used to monitor patients' perception of disease impact/activity. We also noted an intriguing discrepancy between physicians' and patients' evaluations of pulmonary/respiratory symptoms, which requires further investigations.Corona virus disease 2019 (COVID-19) represents the greatest medical crisis encountered in the young history of critical care and res
Like
Comment
Share
